Board of Directors
James B. Wyngaarden, M.D. ׀ Chairman of the Board of Directors
Youssef El Zein ׀ Vice Chairman of the Board of Directors
Sudhir Agrawal, D. Phil. ׀ Director
Robert W. Karr, M.D. ׀ Director
C. Keith Hartley ׀ Director
Hans Mueller, Ph.D.
׀ Director
William S. Reardon, C.P.A. ׀ Director
Alison Taunton-Rigby, Ph.D., OBE ׀ Director
Paul C. Zamecnik, M.D. ׀ Director Emeritus
Hans Mueller, Ph.D. ׀ Director
Dr. Hans Mueller was appointed a member of the Company's board in September 2007. Dr. Mueller most recently served as Senior Vice President of Global Business Development at Wyeth Pharmaceuticals. From 1985 to1993, Dr. Mueller served as Executive Vice President, President and Chief Executive Officer of Nova Pharmaceutical Corporation, now part of Scios, Inc. From 1969 to 1985, he held roles with increasing levels of responsibility at Sandoz, now part of Novartis, in the areas of research, regulatory affairs, manufacturing, systems development, new product planning, licensing and business development. He currently serves on the Board of Directors for Othera Pharmaceuticals and TransMolecular, Inc. and previously served on the Board of Directors for SCOLR Pharma, Inc. and Hypnion, Inc. Dr. Mueller is also an Advisory Board member for Easton Capital. Dr. Hans Mueller received a Ph.D. in Actuarial Sciences and Mathematical Statistics from the University of Bern, Switzerland and is a graduate of Harvard Business School's Advanced Management Program.